Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

Major Program(s) or Research Group(s)

  • Breast and Gynecologic Cancer
  • Phase 0/I/II Cancer Prevention Clinical Trials Program

Sponsor

M.D. Anderson Cancer Center

Status

Recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT03063619

This randomized phase II trial studies how well afimoxifene works in reducing the risk of
breast cancer in women with mammographically dense breast. Estrogen can cause the growth of
breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking
the use of estrogen by the tumor cells.

Intervention

Afimoxifene, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration

Condition

Mammographically Dense Breast

Investigators

Katherine D. Crew, Nagi B. Kumar, Judy E. Garber, Seema A. Khan, Banu Arun, MD

See list of participating sites